Biotech | February 19, 2022
cbdMD becomes first American CBD brand to receive UK validation
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Resolv ER may remedy leading causes of blindness in adults
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Subscribe To Our Newsletter & Stay Updated
